Novacyt S.A. Change of Adviser (7734H)
02 Agosto 2019 - 8:00AM
UK Regulatory
TIDMNCYT
RNS Number : 7734H
Novacyt S.A.
02 August 2019
Novacyt S.A.
("Novacyt", the "Company" or the "Group")
Change of Adviser
Paris, France and Camberley, UK - 2 August 2019 - Novacyt
(EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in
clinical diagnostics, announces that SP Angel Corporate Finance LLP
will be the sole broker to the Company with immediate effect.
- End -
For further information, please refer to www.novacyt.com or
contact:
Novacyt SA
Graham Mullis, Chief Executive Officer
Anthony Dyer, Chief Financial Officer
+44 (0)1223 395472
SP Angel Corporate Finance LLP (Nominated Adviser and
Broker)
Matthew Johnson / Jamie Spotswood (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
+44 (0)20 3470 0470
FTI Consulting (International)
Brett Pollard / Victoria Foster Mitchell/ Mary Whittow
+44 (0)20 3727 1000
brett.pollard@fticonsulting.com/victoria.fostermitchell@fticonsulting.com/
Mary.whittow@fticonsulting.com
FTI Consulting (France)
Arnaud de Cheffontaines / Astrid Villette
+33 (0)147 03 69 47 / +33 (0)147 03 69 51
arnaud.decheffontaines@fticonsulting.com /
astrid.villette@fticonsulting.com
About Novacyt Group
The Novacyt Group is an international diagnostics business
generating an increasing portfolio of in vitro and molecular
diagnostic tests. Its core strengths lie in diagnostics product
development, commercialisation, contract design and manufacturing.
The Company's lead business units comprise of Primerdesign and
Lab21 Products, supplying an extensive range of high quality assays
and reagents worldwide. The Group directly serves oncology,
microbiology, haematology and serology markets as do its global
partners, which include major corporates.
For more information please refer to the website:
www.novacyt.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
APPEAAPAEEENEFF
(END) Dow Jones Newswires
August 02, 2019 09:00 ET (13:00 GMT)
Novacyt (LSE:NCYT)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Novacyt (LSE:NCYT)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024